SCHEMBL2006791

SCHEMBL2006791

NCCC1C(=O)Nc2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 7/20 1.00
GSK3B P49841 2/20 0.58
TDO2 P48775 3/20 0.55
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HTR7 P34969 4/20 0.49
EGFR P00533 1/20 0.45
SRC P12931 1/20 0.45
DRD2 P14416 2/20 0.45
DRD1 P21728 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
ADRA1A P35348 1/20 0.45
HTR6 P50406 1/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16821991 0.98 IDO1 (0.97) IDO1GSK3BTDO2MAPTKDM4E
SCHEMBL1542794 0.87 IDO1 (0.77) IDO1GSK3BTDO2MAPTKDM4E
Hydrochloric Acid SCHEMBL7419440 0.85 IDO1 (0.74) IDO1GSK3BTDO2MAPTKDM4E
SCHEMBL8034325 0.82 IDO1 (0.70) IDO1GSK3BTDO2MAPTKDM4E
SCHEMBL397709 0.82 IDO1 (0.70) IDO1GSK3BTDO2MAPTKDM4E
SCHEMBL7041168 0.82 IDO1 (0.70) IDO1GSK3BTDO2MAPTKDM4E
SCHEMBL319056 0.79 IDO1 (0.66) IDO1GSK3BTDO2MAPTKDM4E
SCHEMBL16264954 0.79 IDO1 (0.66) IDO1GSK3BTDO2MAPTKDM4E
SCHEMBL1456203 0.78 IDO1 (0.64) IDO1GSK3BTDO2MAPTKDM4E
SCHEMBL2260925 0.78 IDO1 (0.64) IDO1GSK3BTDO2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2631238-A1 Spirocyclic inhibitors of serine proteases for the treatment of hcv infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-28 EP disclosed
US-8440706-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-14 US disclosed
EP-1917269-B1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMA (US) 2011-10-26 EP disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 IDO1 2612/4885GSK3B 2199/4885TDO2 4487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.